Introduction
Many human single gene defects affect one or more hematopoietic lineages and therefore, hematopoietic stem cells are important targets for therapeutic gene transfer. During the past 15 years, substantial effort has been invested in adapting available murine oncoretroviral vector systems for gene transfer into hematopoietic stem cells. The current generation of retroviral vectors can readily transduce a significant proportion of mouse stem cells, 1, 2 but the genetic modification of repopulating cells of humans, non-human primates and other large outbred animals has been much less successful. [3] [4] [5] Because oncoretroviral vectors require cell division for genome integration, the quiescent nature of stem cells in larger species constitutes a barrier to successful transduction. Furthermore, the receptor utilized by amphotropic vec- tion (less than 4%), but transduction increased to 23 ± 2% after 2 days of cytokine stimulation and was further augmented by addition of tumor necrosis factor ␣ (51 ± 4%) at a multiplicity of infection of 10 6 . rAAV-mediated gene expression was transient in that progenitor derived colony formation was inhibited by trimetrexate. Primitive CD34 + and CD34
− subsets were sequentially transduced with a rAAV vector encoding the murine ecotropic receptor followed by transduction with an ecotropic retroviral vector encoding GFP and DHFR. Under optimal conditions 41 ± 7% of CD34 + progenitors and 21 ± 6% of CD34 + , CD38 − progenitors became trimetrexate resistant. These results document that highly purified rAAV transduce primitive human hematopoietic cells efficiently but gene expression appears to be transient. Gene Therapy (2000) 7, 183-195. tors to transduce human cells is now known to be expressed at low levels on primitive hematopoietic cells. 6 Alternative vector systems based on adeno-associated virus (AAV), lentiviruses or foamy viruses are being explored in an effort to overcome the barriers to human stem cell targeted therapeutic gene transfer. 7 The properties of recombinant AAV (rAAV) vectors that make them attractive for hematopoietic stem cell transduction have been reviewed before. 8 Early studies suggested that rAAV vectors could transduce primitive human hematopoietic cells. [9] [10] [11] [12] [13] [14] However, these studies were performed with crude vector preparations composed of lysate derived from producer cells, which had been infected with adenovirus and co-transfected with the vector plasmid and a packaging plasmid encoding the AAV proteins. Such preparations contain wild-type AAV, which arises by virtue of non-homologous recombination between the vector and packaging plasmids. The vector encoded gene product is also present in such crude lysates raising the possibility of pseudo-transduction accounting for apparent enzymatic activity in target cells. 15 Furthermore, the presence of plasmid DNA and the use of high multiplicity of infection (MOI) raise the possibility that contaminating DNA accounted for PCR signals. Some of these concerns were reduced by purification of vector particles on cesium chloride gradients, but such preparations contain variable amounts of denatured adenoviral particles, 16 wild-type AAV [17] [18] [19] and residual plasmid DNA. 15 Demonstration of a rAAV encoded RNA product under the control of an erythroidspecific transcriptional elements in erythroid, but not myeloid, colonies derived from transduced progenitors provided some of the strongest evidence that rAAV could transfer and express a gene in primitive human hematopoietic cells. 13, 17 Equally convincing was the correction of a defect in DNA repair which allowed colony formation by transduced progenitors from patients with Fanconi anemia in the presence of drug selection.
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Previous studies with rAAV in tissue culture cells utilized selection to recover drug-resistant clones, which were then shown to contain an integrated pro-viral genome. 14, 20 Such studies are totally uninformative with regard to the efficiency of rAAV integration. More recent studies have unequivocally demonstrated that vector uptake, conversion of the single-stranded to a doublestranded genome, and episomal-mediated, rAAV gene expression can occur without genome integration. 17, 21, 22 Indeed, rAAV have proved most useful for transducing quiescent, differentiated cells in vivo such as hepatocytes, 23 muscle cells 24 and neurons, 25 in which the genome persists as a high molecular weight episomal or integrated concatamer. The rAAV genome is rapidly diluted out and lost from proliferating cells although transduction of such cells at higher MOI has been shown to increase the frequency of genome integration. 17, 26 In the context of these new insights into the biology of rAAV, we interpret our earlier studies in which primary progenitors were transduced and expressed the rAAV encoded product over 10-14 days as reflecting transient, episomal-mediated gene expression. This interpretation is supported by the fact that attempts to transduce repopulating stem cells in a non-human primate model have been unsuccessful (Hargrove, Donahue and Nienhuis, unpublished observations) or resulted in a very low level of gene transfer. 27 However, other investigators have reported transduction of human long-term culture initiating cells (LTC-IC) or murine repopulating cells with stable rAAV genome integration as reflected by fluorescent in situ hybridization (FISH) analysis of metaphase chromosomes or persistence of the genome in high molecular weight DNA over extended periods of time. 9, 28 Recently there have been a number of advances in the production of rAAV. Preparations entirely free of adenovirus can be obtained by substituting a plasmid, which encodes the required adenoviral gene products for the helper virus. 16, [29] [30] [31] A reduction in the risk for generation of wild-type AAV (wt-AAV) has been achieved by rearranging the coding sequences for AAV proteins in the packaging plasmid. 32 Column chromatography has been substituted for cesium chloride gradient centrifugation as a purification step, improving the ratio of biologically active to physical particles in the final preparations. 33, 34 We have now adapted these improvements in vector production technology to generate high-titer vector preparations free of wt-AAV and adenovirus proteins. Such preparations have been used to re-evaluate the transduction of primitive human hematopoietic cells. rAAV-mediated gene expression proved transient, although expression of the murine retroviral ecotropic receptor from a rAAV genome permitted high efficiency transduction of human progenitors with a murine ecotropic retroviral vector. Exposure of cells transduced with rAAV to tumor necroses factor ␣ (TNF␣) increased transduction efficiency two-to three-fold.
Results
Production of rAAV using split packaging plasmids To reduce the possibility of wt-AAV contamination, we split the rep and cap genes into a series of independent transcription units ( Figure 1 ) thus reducing the possibility of recombination. Western blot analysis of cellular lysate from 293T cells transfected with pRep-Ad showed that expression and migration of the Rep proteins was similar to that seen with AAV/Ad (Figure 2a ). In addition, inactivation of the p40 promoter in plasmid pRep-Ad (p40*) had little effect on rep protein expression. The three capsid proteins, VP1, VP2, VP3, were expressed by the p40-Cap plasmid in almost the same ratio as AAV/Ad (Figure 2b ). Synthesis of all three capsid proteins was enhanced when the CMV IE promoter replaced p40 in the CMV-Cap construct.
We next examined the ability of CMV-Cap and pRepAd to propagate rAAV in comparison with AAV/Ad. A large-scale preparation (10, 15-cm plates with approximately 10 7 cells each) of rAAV CMV-GIL was made in the conventional manner by transfecting 293T cells with AAV/Ad and vector plasmid pAAV CMV-GIL followed by adenovirus infection. In addition, two large-scale preparations were made using the split packaging plasmids CMV-Cap and pRep-Ad, in 3:1 molar ratio, together with the bicistronic AAV vector, using either wild-type adenovirus or 80-XX6 adeno plasmid for helper function. Particle and functional titers determined for each preparation as outlined in the Materials and methods section are summarized in Table 1 . The rAAV preparation made in the conventional manner with AAV/Ad and adenovirus were contaminated with wt-AAV at a level of 3.2% of rAAV particle yield. Substitution of AAV/Ad with the split packaging plasmids resulted in wild-type free rAAV preparations as determined by slot blot analysis and a PCR assay capable of detecting 1 wt-AAV in 10 7 rAAV particles. Consistent with other reports, 16, 29 we observed a significant increase in the particle and functional titer of rAAV vector preparation made with 80-XX6 instead of adenovirus.
Next we compared the yield of rAAV purified using a heparin affinity purification method 34 based on the observation that heparan sulfate proteoglycan serves as the receptor for AAV. 35 rAAV stocks purified with this method contain significantly lower levels of contaminating proteins than those derived by the conventional CsCl density gradient centrifugation. 34 The mean particle yield for heparin column purified preparation and rAAV samples purified by CsCl centrifugation was 4.9 × 10 11 and 1.39 × 10 11 , respectively. However, the biological activity of the heparin column purified preparations on 293T cells was over four-fold higher compared with the CsCl method resulting in a significant difference between the particle and function ratios of the two sets of preparation (Table 1 ). 
Parameters for transduction of cord blood derived CD34
+ cells The helper and wild-type free rAAV vector preparations were used to define the factors that influence transduction of human cord blood (CB) derived hematopoietic stem cells (HSC). Human CB CD34
+ cells were transduced with rAAV CMV-GIL either immediately upon isolation or following pre-stimulation for 48 h in the intermediate-dose (IDC) or high-dose (HDC) cytokine cocktail (see Materials and methods for cytokine concentrations). Transductions were typically performed Gene Therapy overnight at a variety of MOI using at least three different CsCl and 2-heparin column purified preparations. Each preparation was used at least once to evaluate transduction efficiency. Pseudo-transduction was excluded by exposing CD34 + cells to an identical volume of pseudorAAV stocks (see Materials and methods). The pseudorAAV transduced cells were otherwise processed in an identical manner to the rAAV-transduced cells. The results are summarized in Figure 3 .
Transduction of CD34 + cells with rAAV CMV-GIL, at an MOI below 10 6 , resulted in low (Ͻ2%) and inconsist- ent GFP expression. Therefore further evaluation of the transduction parameters with this vector was performed at an MOI of 10 6 , which was the highest that could be achieved with the available rAAV preparations. Freshly isolated CD34
+ cells were relatively resistant to transduction with rAAV CMV-GIL resulting in a mean of 2.5 ± 1.0% CD34 + cells expressing GFP. This value increased by four-fold for cells that had been cultured in media containing IDC before transduction. Pre-stimulation of CB CD34
+ cells in the HD cytokine cocktail gave the best transduction efficiency with a mean of 23 ± 2.0% of the cells expressing GFP. This difference in transduction efficiency was consistent and reproducible with multiple preparations of rAAV. Furthermore, when prestimulated with HDC, the transduction efficiency of heparin column purified rAAV CMV-GIL preparations was similar to CsCl-derived vector with a mean of 26% and 21% of CB CD34
+ cells expressing GFP, respectively. We did not observe significant variation in transduction efficiency of individual cord blood CD34
+ samples that has been reported by others. 28, 36 To determine if HDC enhanced rAAV transduction efficiency was blocked by an inhibitor of cell-cycling, we pre-stimulated CD34
+ cells in SF media containing HDC and 10 ng/ml of TGF␤1, a potent inhibitor of HSC cycling. 37, 38 These cells when exposed to rAAV CMV-GIL at an MOI of 10 6 exhibited a low transduction efficiency (3.0 ± 1.0% GFP positive cells) that was comparable to levels observed in freshly isolated unstimulated CB CD34 + cells. In contrast inclusion of TNF␣ (10 ng/ml), another inhibitor of stem cell cycling, 39 in the HDC prestimulation cocktail, resulted in a two-fold increase (51.0 ± 4.0%) in the number of cells expressing GFP and in the mean GFP levels. Similar results were obtained when CD34
+ cells were exposed to TNF␣, 24 h after transduction with rAAV CMV-GIL ( Figure 4 ). This suggests that TNF␣ increases transgene expression by influencing events after entry of rAAV into the cells. However, in the absence of further TNF␣ exposure the GFP expression declined to levels observed in non-TNF␣ induced cells over a period of 4 days. Prolonged exposure of CD34 + cells to TNF␣ in the presence of cytokines leads to differentiation into dendritic cells. 40 However, the short exposure to TNF␣ required for increased rAAV transgene expression, did not result in an increase in dendritic cell surface markers CD1a and CD14 (data not shown).
The durability of transgene expression was determined by monitoring GFP expression by rAAV CMV-GIL transduced CD34
+ cells that were maintained in liquid culture in the presence of IDC. The number of cells expressing GFP decreased over time from 18% at 48 h after transduction to 2.5% at 10 days. When rAAV CMV-GIL transduced CB CD34 + cells were plated in semisolid culture media in the presence or absence of trimetrexate (150 nm/l), fewer than 1.0% of the progenitors were resistant to trimetrexate at 14 days as a result of expression of the L22Y DHFR variant from the rAAV transgene. Furthermore, TNF␣ exposure did not result in a significant increase in the number of clonogenic progenitors resistant to trimetrexate.
Sequential transduction of hematopoietic precursors is enhanced by TNF␣
To determine if the effect of TNF␣ was transgene specific, we transduced K562 erythroleukemia cells with a rAAV vector containing the murine ecotropic retroviral receptor (EcoRec) cDNA under the control of the CMV promoter (rAAV CMV-EcoRec). Half of the AAV transduced cells were exposed to TNF␣ for 12 h. Then both the uninduced and the TNF␣ induced cells were exposed to an ecotropic retrovirus MGirL22Y, (a bicistronic retroviral vector containing GFP and mutated DHFR gene under the control of the MSCV-LTR promoter), at an MOI of 2. The rAAV and retroviral transduction efficiency was determined by assessing EcoRec and GFP expression, respectively.
The level of EcoRec expression on K562 cells increased with increasing rAAV MOI (Figure 5a) . Exposure of the rAAV transduced K562 cells to TNF␣ increased EcoRec expression by on average two-fold. Cells exposed to pseudo-rAAV CMV-EcoRec stocks (mock) were resistant to infection by ecotropic retrovirus, MGirL22Y. In con- Transducing units were determined by exposing 1 × 10 5 293T cells to serial dilutions of the vector, followed by assessment of the level of transgene expression at 48 h after transduction. The final volume for each preparation was between 1.5 to 2 ml. The difference in the particle to infectivity ratio between the CsCl and the heparin column purification methods as determined on 293T cells is significant (P = 0.019 using unpaired Student's t test).
Figure 3 Parameters influencing transduction of CB CD34
+ cells with rAAV CMV-GIL. GFP trast, a direct correlation was observed between the level of EcoRec expression and transduction with the ecotropic retrovirus, as reflected by the number of K562 cells expressing GFP (Figure 5b ).
Based on these results, CB CD34 + were sequentially transduced with rAAV CMV-EcoRec and ecotropic retrovirus, MGirL22Y. As with K562 cells, transduction of CB CD34
+ cells with rAAV CMV-EcoRec facilitated infection with ecotropic retrovirus, MGirL22Y in a dose-dependent manner. Thus at the highest MOI of 3.8 × , resulted in consistent and reliable infection with ectropic retrovirus suggesting that the sequential transduction strategy provided a more sensitive measure of the ability of rAAV vector to transduce CD34
+ cells ( Figure 6 ).
The transduction efficiency of the hematopoietic clonogenic progenitors was determined by plating a proportion of the sequentially transduced CD34
+ cells in methylcellulose in the presence or absence of TMX (150 nm/l). The results summarized in Table 2 indicate that sequential transduction of CB CD34
+ cells resulted in sustained retroviral transgene expression in a significant proportion of the clonogenic hematopoietic colonies with 12 ± 2.0% progenitors exhibiting TMX resistance without TNF␣ exposure. Predictably, the number of progenitors conferred TMX resistance was higher after exposure to TNF␣ (41 ± 7.0%).
The rAAV transduction efficiency of the CD38 − fraction of the CD34 + population was also determined. The CD34 + CD38 − subset was isolated from the CD34 + enriched population by FACS selection as described in the Materials and methods (and outlined in Figure 7a ). These cells were pre-stimulated for 48 h with HDC and then transduced overnight with rAAV CMV-EcoRec at an MOI of 10 6 in the presence or absence of TNF␣. The cells were then exposed to MGirL22Y at an MOI of 2 and the retroviral transduction efficiency determined by assessing GFP expression (Figure 7) . Approximately 12 ± 4.0% of the CD34 +
CD38
− cells expressed GFP as a result of transduction with ecotropic retrovirus MGirL22Y. Exposure of the rAAV CMV-EcoRec transduced CD34 +
− cells to TNF␣ further increased the ecotropic retroviral transduction efficiency to 21 ± 6.0%.
Discussion
Central to the evaluation of rAAV vectors for clinical use is the production of high titer preparations that are free of wt-AAV and contaminating helper viral proteins. Our data establish that the AAV rep and cap genes can function independently of each other and can be used in conjunction with a helper plasmid to produce rAAV preparations that are free of wt AAV and adenovirus. We used these preparations to determine the factors that 
. The induced and the uninduced cells were then transferred to individual wells of a 48-well plate coated with recombinant human fibronectin fragment (CH-296) and exposed to ecotropic retrovirus, MGirL22Y, at an MOI of 2. The CD34 and GFP expression in uninduced and TNF␣ induced cells 24 h after retroviral transduction is shown by the left and right panel, respectively. GFP expression in cells exposed to pseudo-AAV stock instead of rAAV CMV-EcoRec but exposed to MGirL22Y (mock transduced) is represented in the top panel. influence transduction of primary hematopoietic progenitors. Efficient transduction of CB-derived CD34
+ cells with rAAV vectors required high MOI and prestimulation of the cells with high doses of cytokines. Short exposure of the rAAV transduced hematopoietic precurors to TNF␣ results in a two-fold increase in transgene expression. However, transgene expression in CB CD34 + cells was transient, consistent with expression from an episomally maintained transgene although silencing of integrated provirus cannot be excluded. Transient rAAV transgene expression was exploited to express the murine ecotropic retroviral receptor in primary hematopoietic stem cells thus making these cells susceptible to transduction by ecotropic retrovirus. The retroviral transduction efficiency as reflected by the proportion of GFP expressing cells and the number of drug resistant clonogenic Gene Therapy progenitors increased in parallel with the MOI of rAAV CMV-EcoRec suggesting that receptor expression may limit retroviral transduction of human CD34 + cells. The level of contamination of rAAV stocks with wt-AAV varies from between 0.01% to 10%. 17, 19, 41 In addition rAAV preparations made by conventional means are often contaminated with adenoviral structural and fiber proteins despite extensive purification and adenovirus inactivation measures. 16 Apart from raising concerns of an immunogenic response following in vivo administration 42, 43 these contaminants could modify the behavior of rAAV by influencing transduction efficiency 44, 45 or by affecting the conversion of single-to double-stranded genomes. 46 We, therefore, made three significant changes to our rAAV production protocol in order to make a more defined rAAV vector preparation. Using the split + cells were plated in duplicate in methylcellulose in the presence or absence of trimetrexate (150 nm/l). Colonies were enumerated after 14 days. The results shown here are from four different experiments and the data are depicted as number of drug resistant colonies over the number of colonies observed without drug selection. Mock-transduced CD34
+ cells were exposed to pseudo-AAV stock (instead of rAAV CMV-EcoRec) followed by ecotropic retrovirus MGirL22Y. Although results show total number of colonies, both myeloid and erythroid colonies were conferred resistance to trimetrexate and the proportion of these respective colonies was similar to that observed with mock-transduced, non-drug treated plates. The difference in the number of TMX resistant colonies observed in the absence of TNF␣ or following exposure to TNF␣ is significant (P = 0.027 using unpaired Student's t test). packaging plasmids, we were able to produce rAAV stocks that were free of wt-AAV as determined by a PCR assay capable of detecting 1 wt-AAV particle in 10 7 rAAV genomes. Adenovirus was eliminated from the rAAV preparation by using a helper plasmid, which contains the essential helper genes (VA, E2A and E4a) but lacks the adenoviral structural and replications genes. Finally, we adopted a heparin column chromatography method for purifying rAAV as a number of groups had reported a marked reduction in contaminating proteins and improved biological activity of rAAV preparation compared with stocks derived with the conventional CsCl centrifugation method. 33, 34 We used these highly purified rAAV preparations to address the controversy surrounding rAAV-mediated transduction of primary hematopoietic progenitors. Our data indicates that freshly isolated CB CD34 + cells are poorly transduced with rAAV vectors even at high MOIs. Optimal transduction required prestimulation of hematopoietic progenitors with high doses of cytokines. This is consistent with our previous observations 17 and those of two other groups. 26, 27 Although the heparin column purified rAAV preparations had a better biological activity on 293T cells, their CD34 + cell transducing potential was comparable to CsCl purified vector. This suggests that at the very high MOI, rAAV may enter the cell through a mechanism that is distinct from that used to assess functional titer on 293T cells.
We speculate that high-dose cytokines increase stem cell cycling leading to higher transduction rates when compared with unstimulated hematopoietic progenitors. This is supported by the observation that TGF␤I, a potent inhibitor of hematopoietic stem cell cycling 37, 38 reduced rAAV transduction efficiency to the levels observed with non-stimulated cells. Furthermore, others have demonstrated preferential transduction of cells in S-phase by 191 AAV vectors. 47 We cannot, however, exclude the possibility of high-dose cytokines potentiating rAAVmediated transduction of CD34 + cells by other mechanisms such as up-regulation of heparan sulfate or ␣V␤5 integrin which mediate AAV entry into cells. 35, 48 Indeed up-regulation of ␣v␤5 integrin on the surface of monocytes by GM-CSF facilitated adenovirus-mediated gene transfer. 49 Interestingly, exposure of rAAV transduced CB CD34 + cells to TNF␣, another inhibitor of hematopoiesis, results in a two-fold increase in transgene expression. However, this increase was only transient and declined rapidly to levels observed in non-induced cells in the absence of further stimulation. There are a number of possible explanation for the effect of TNF␣ on CD34 + cells. We initially speculated that TNF␣ might increase transgene expression in CD34
+ cells by increasing second-strand synthesis possibly by reducing the phosphorylation of a cellular D region binding protein, ss-D-BP, mediated by the protein-tyrosine kinase activity of epidermal growth factor receptor (EGFR). 50 Studies in K562 erythroleukemia cells transduced with rAAV CMV-GIL, however, suggest that TNF␣ induction leads to an increase in GFP expression but does not change the phosphorylation status of ss-D-BP (unpublished observation). Furthermore, TNF␣ also increased GFP expression in K562 cells transfected with the rAAV precursor plasmid CMV-GIL, implying that the effect of TNF␣ was independent of the natural biology of AAV. A number of studies have suggested that the TNF␣ can enhance the activity of the CMV-IE enhancer/promoter region. 51, 52 Consistent with this we documented a two-fold increase in transgene mRNA following exposure to TNF␣ in K562 cells that had stable expression of the rAAV CMV-GIL provirus (unpublished observation). Furthermore, TNF␣ exposure did not result in increased transgene expression in K562 cells transduced with rAAV MSCV-GIL, an AAV vector in which the CMV promoter of the AAV CMVGIL cassette was replaced with the murine leukemia virus promoter (unpublished observation). TNF␣ also increased the expression of the EcoRec expression in CD34
+ cells transduced with a rAAV vector in which the CMV promoter controlled expression of the EcoRec gene indicating that the effect of TNF␣ was not transgene specific. We believe that TNF␣ through its action on the CMV promoter, increases the level of the transgene expression in cells that were previously scored negative because the transgene expression was below the detection threshold. This implies that rAAV vectors transduce CD34 + cells more efficiently than was at first realized and highlights the importance of a strong promoter when assessing gene transfer. Using the sequential transduction strategy we have unequivocally demonstrated that rAAV vectors that are free of helper virus and wt-AAV contamination can transduce the CD34 +
CD38
− subset of CD34 + which harbors the repopulating stem cells. 53, 54 Although CB CD34 cells were efficiently transduced, the transgene expression appeared to be transient. We observed a similar trend in K562 cells 17 where very high MOIs were required for stable integration of the rAAV transgene and these findings have been independently confirmed by others. 26 Some investigators however, report efficient and long-term transduction of human 9, 14, 28, 36, 55 and murine hematopoietic progenitors 20 using relatively low rAAV MOIs. Even allowing for variGene Therapy ation in vector design and reporter genes there are several notable differences in the way these studies were performed. Some were performed using crude rAAV preparations. 9, 14, 20 Such preparations are contaminated with vector encoded marker proteins, as well as nucleic acids which can be transferred to the target cells in a virus-independent manner 15 leading to the erroneous interpretation of transduction. In addition, the presence of adenoviral proteins can influence transduction of these cells, as well as transgene expression. 46 Furthermore, the transduction efficiency with rAAV in all these studies was based on DNA PCR, which should be interpreted with caution since such an assay reflects the presence of the rAAV genome, which may not correlate with transduction or transgene expression. Despite reporting prolonged expression, none of these studies have convincingly demonstrated integration of the rAAV transgene stably into the host genome using conventional Southern blot analysis. This is particularly important, as prolonged episomal rAAV expression in post-mitotic cells has been widely documented. [23] [24] [25] It is, therefore, conceivable that CD34 + cells transduced without cytokine pre-stimulation and then maintained in low doses of cytokines would divide less frequently and thus maintain an episomal copy of the transgene for longer. Under these circumstances, persistence of transgene by PCR may not indicate integration of the provirus in the host genome. The demonstration of rAAV proviral sequences within the genome of LTC-IC by FISH analysis, thus far is the strongest evidence supporting the integration of the rAAV transgene in primitive clonogenic progenitors. 28 However, the reported integration frequency is much higher than that observed in other tissues such as the liver. 56 In addition as LTC-IC are distinct from hematopoietic stem cells with long-term engraftment capability further studies with in vivo models of hematopoiesis are required to evaluate the true potential of this observation. 57 In conclusion, highly purified rAAV preparations that are free of adenovirus and wt-AAV mediate efficient gene transfer and expression in primary human hematopoietic progenitors that declines steadily over time. The efficiency of stable integration appears to be low and may be improved by using higher rAAV titers, but this will require further improvement in rAAV production technology. The episomal expression of rAAV can be exploited to make primitive human hematopoietic progenitors amenable to transduction with murine ecotropic retroviral vectors leading to sustained transgene expression.
Materials and methods
Cell culture and viruses Mouse NIH 3T3 fibroblasts, human cervical carcinoma (HeLa) cells, human embryonic kidney cells (293T), and human erythroleukemia, (K562) cells, were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 U of penicillin per ml and 0.1 mg of streptomycin per ml (D10), at 37°C in a humidified atmosphere containing 5% CO 2 . Wild-type adenovirus type 5 was propagated on 293 cells and purified by two sequential rounds of buoyant density ultra-centrifugation in CsCl. The producer cell line for the ecotropic retroviral vector MGirL22Y which has been described before, 2 is derived from the GP+E86 packaging cell line (ATCC; CRL-9642) and maintained in D10. Medium containing retrovirus particles was collected once the producer cells reached confluency, filtered through a 0.45 m pore size filter, divided into aliquots and stored frozen at −80°C until needed. The titer of MGirL22Y retroviral stocks was estimated to be 1-5 × 10 5 infectious units/ml by flow cytometric assay of GFP expression by NIH3T3 cells transduced with serial dilutions of the vector preparation.
Construction of vectors, split packaging and adenohelper plasmids
The bicistronic recombinant AAV vector, pAAV CMV-GIL, was constructed by cloning a 2043bp EcoRI-NsiI fragment, derived from plasmid MGirL22Y, 58 containing the green fluorescent protein (EGFP) and the L22Y variant of DHFR genes separated by the encephalomyocarditis virus internal ribosomal entry site, into the EcoRI and PstI sites of pcDNA3.1/Zeo+ (Invitrogen, Carlsbad, CA, USA), 3Ј to the CMV promoter. Subsequently a 3959 bp, SspI-NsiI, fragment was isolated from this intermediate plasmid and cloned into SnaBI and NsiI sites of a pSUB201. 59 Plasmid pAAV CMV-EcoRec was derived by inserting a BamHI fragment encompassing the cDNA encoding the ecotropic retroviral receptor (EcoRec) 60 into the respective site of pcDNA3.1/Zeo+. The CMV-EcoRec expression cassette was subsequently excised with MunI and EcoRV and ligated into the corresponding sites of pAAV CMV-GIL ( Figure 1) .
The split packaging plasmids were made by separating the rep and cap coding sequence in packaging plasmid AAV/Ad 61 into independent transcriptional units. Plasmid pRep-Ad consisted of the rep open reading frame under the control of its endogenous promoters and was derived by deleting the cap coding sequences (nucleotides (nt) 2194 to 4153; numbering according to Srivastava et al 62 from pAAV/Ad). In pRep Ad (p40*) the p40 promoter TATA sequence, within the rep open reading frame of pRep-Ad, was mutated to CATT. Plasmid p40-Cap was constructed by deleting the rep promoters and coding sequences from AAV/Ad by XbaI partial and NspV restriction digestion. In pCMV-Cap the p40 cap promoter was replaced with CMV IE promoter ( Figure  1 ). The adeno-helper plasmid (80-XX6) was made by ligating a SalI-ClaI 15.8 kbp fragment containing the adenoviral genes essential for rAAV production 34 into the XhoI and BstBI sites of plasmid pSLII80 (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The function of the split packaging plasmids was determined by transfecting 10 g of each plasmid or AAV/Ad into 1 × 10 5 293T cells in six-well plates. A cell lysate was prepared 48 h after transfection by adding 200 l of 2 × SDS lysis buffer (125 mm Tris HCl pH 7.5, 4% SDS, 10% glycerol, 0.02% bromophenol blue) directly to the wells. The lysed cells were transferred to an Eppendorf tube, heat inactivated for 10 min before loading on to a 10% SDS polyacrylamide gel. Following electrophoresis, the proteins were transferred to a nitrocellulose membrane. The AAV proteins were detected by standard techniques using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech). Mouse monoclonal antibodies for rep and cap proteins were obtained from American Research Products (Boston, MA, USA).
Recombinant AAV vector production Semiconfluent 293T cells on 15-cm plates were co-transfected, with split packaging plasmids pRep-Ad (2.5 g) and CMV-Cap (7.5 g), and vector plasmid, (either pAAV CMV-GIL or pAAV CMV-EcoRec 10 g) using Superfect (Qiagen, Valencia, CA, USA) according to the manufacturers' instructions. The next day the cells were infected with adenovirus at a multiplicity of infection (MOI) of 10 for 1 h and incubated for an additional 48 h until cytopathic effect became visible. Production of rAAV, free of helper virus involved a four-way transfection of approximately 1 × 10 7 293T cells on 15 cm plates with pRep-Ad (2.5 g), pCMV-Cap (7.5 g), vector plasmid (10 g) and 80-XX6 (30 g), a plasmid that encodes the adenoviral helper genes necessary for the productive life cycle of AAV. No cytopathic effect was evident under these conditions and the cells were harvested 48 h after transfection. A clarified cell lysate was prepared by five cycles of freeze thaw followed by centrifuged at 6000 g for 10 min to remove cell debris. Viral stocks made with adenovirus were incubated at 56°C for 30 min to inactivate the helper virus.
The rAAV preparation were purified further either by the conventional CsCl isopynic density centrifugation 21 or the heparin column chromatography method of Zolotukhin et al. 34 This latter method required the initial removal of cellular debris by discontinuous step gradient centrifugation using Iodixanol (Nycomed, Princeton, NJ, USA). The viral fraction was then applied to a 2.5 ml heparin agarose type I column (Sigma, St Louis, MO, USA) equilibrated with PBS containing 1 mm MgCl 2 , 2.5 mm KCl (PBS-MK). The column was washed with 10 ml of PBS-MK and the virus eluted with 3.5 ml of PBS containing 1 m NaCl.
Pseudo-rAAV stocks, were made by transfecting 293T cells with pRep-Ad, pAAV CMV-GIL and 80-XX6 at the concentrations stated above. Some pseudo-rAAV stocks were made by substituting 80-XX6 with adenovirus infection. The transfected cells were harvested and purified in exactly the same manner as rAAV producer cells.
rAAV vector titer and purity To determine functional titer 1 × 10 5 293T were transduced overnight in serum-free media with serial dilutions of the rAAV CMV-GIL or rAAV CMV-EcoRec vectors. The cells were washed the next day and cultured in D10 for a further 48 h before assessment of transduction efficiency. Flow cytometric determination of GFP expression by 293T cells indicated rAAV CMV-GIL vector transduction efficiency. A virus-binding assay 21 was used to assess ecotropic receptor expression following transduction with AAV CMV EcoRec. Recombinant vector and wt AAV particle numbers were determined by slot blot analysis as previously described. 21 Contamination of rAAV preparations with wt-AAV was also determined by a PCR-based assay. In brief, DNA extracted from approximately 1 × 10 10 rAAV particles was subjected to 35 cycles amplification using primers ITR-1 (5Ј-CTCCATCACTAGGGGTTCC-3Ј), located in the D region of the 5Ј ITR and R-1 (5Ј-GGCA-GATGCCCGTCAAGGT-3Ј) from the 5Ј portion of the rep gene. These primers were specifically designed to detect a 150 bp region between the 5Ј ITR and the rep gene that would result from recombination between vector and the packaging plasmids. Positive controls consisted of serial 193 dilutions (10 2 -10 5 genomic copies) of plasmid DNA containing the wt AAV genome. The viral DNA was subjected to PCR under the same conditions with primers (GFP 1 5ЈGTCCAGGAGCGCACCATCTT3Ј and GFP2 5ЈCTCGTCCATGCCGAGAGTGA3Ј) designed to amplify a 429 bp region of the green fluorescent protein within the rAAV genome to confirm the integrity of the template. The PCR products were resolved on polyacrylamide gel and quantitated using a phosphoimager. Using this assay it was possible to detect wt-AAV contamination to a sensitivity of 1 wt-AAV in 10 7 rAAV genomes. Aliquots of rAAV were periodically subjected to polyacrylamide gel electrophoresis and electron microscopy to verify that preparations were free of adenovirus and cellular contamination.
Isolation of cord blood hematopoietic progenitors Samples of umbilical cord blood (CB) were obtained from discarded placental and umbilical tissues by drainage of blood into sterile collection bags. Mononuclear cells were isolated by layering the blood on to Ficoll-Hypaque (1.077 g/ml; Sigma) and centrifugation at 400 g for 30 min at room temperature. CD34
+ cells were enriched from this population by depletion of lineage positive cells using the MiniMACs (Myltenyi Biotech, Auburn, CA, USA) magnetic separation kits according to the manufacturer's specifications. The purity of the CD34 + population ranged from 85% to 98% as evaluated by flow cytometry using fluorescein isothiocyanate conjugated mouse anti-human CD34 (FITC) and phycoerythrin (PE) labeled mouse antihuman CD38 antibodies (Becton Dickinson, San Jose, CA, USA).
The CD34 + CD38 − subset was isolated from purified CD34 + cells by staining these cells with mouse antihuman CD34 and CD38 antibodies followed by a sterile sort for cells with the lowest CD38 expression, using a FACS Vantage flow cytometer (Becton Dickinson).
Transduction of hematopoietic progenitors Cord blood derived CD34
+ cells were transduced with rAAV CMV-GIL either immediately upon isolation or following 48 h of pre-stimulation with cytokines. Two different cytokine cocktails were used for pre-stimulation; intermediate dose cytokine cocktail (IDC) consisted of interleukin-3 (IL-3) 20 ng/ml, interleukin-6 (IL-6) 50 ng/ml and stem cell factor (SCF) 50 ng/ml and high-dose cytokine cocktail (HDC) which contained IL-3; 20 ng/ml, IL-6; 50 ng/ml SCF; 300 ng/ml and Flt3 ligand 300 ng/ml. Transductions were typically performed by exposing 5 × 10 4 freshly isolated or cytokine-stimulated CB CD34
+ with the desired amount of rAAV in 48-well polystyrene plates (Corning, New York, NY, USA). The transduction mix was incubated overnight in a total volume of 200 l of serum-free IMDM in a 5% CO 2 humidified atmosphere at 37°C with periodic rocking of the plate. The cells were then washed and cultured in media containing IDC for 24 to 48 h before flow cytometric determination of GFP expression or plating in semi-solid media as described below.
Sequential transduction of CD34 + cells consisted of prestimulation for 48 h in HDC media followed by overnight transduction with rAAV CMV-EcoRec as described above. The cells were then washed twice in PBS and transferred to 48-well plates coated with 10 g/cm 2 recombinant fibronectin fragment CH-296 (Takara Shuzo,
Gene Therapy
Otsu, Japan). They were then exposed to IMD cytokine supplemented conditioned media from the MGirL22Y retrovirus producer cells, three times, at a MOI of approximately 2, over a period of 36 h. The rAAV transduction efficiency was determined by assessing ecotropic receptor expression using a virus-binding assay as described before. 21 GFP expression by the CD34 + cells indicated the ecotropic retroviral transduction efficiency.
To determine the transduction efficiency at the clonogenic progenitor level, CD34
+ cells transduced with either rAAV CMV-GIL or sequentially transduced with rAAV CMV-EcoRec and MGirL22Y retrovirus were plated in methylcellulose containing appropriate cytokines (Methocult H4230; Stem cell Technologies, Vancouver, British Columbia, Canada) which had been pretreated with 3 U thymidine phosphorylase (Sigma) at 37°C for 2 h. The cells were subjected to selection with trimetrexate (150 nmol/l) and the hematopoietic colonies enumerated at 10-14 days of culture.
